|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o AEterna Laboratories Inc., of Quebec City, and its wholly owned subsidiary Zentaris GmbH reported statistically significant positive results from a recently completed Phase II program designed to evaluate cetrorelix in three different indications: endometriosis, pre-surgical treatment of uterine myomas and benign prostatic hyperplasia. The findings, which also demonstrated good tolerability in all indications, will form the basis for further development of cetrorelix in different indications through a collaboration with Solvay Pharmaceuticals BV, of Brussels, Belgium. More detailed data, along with a new depot formulation of the luteinizing hormone-releasing hormone ...